Although disruption of DNA repair capacity is unquestionably associated with cancer susceptibility in humans and model organisms, it remains unclear if the inherent tumor phenotypes of DNA repair deficiency syndromes can be regulated by manipulating DNA repair pathways. Loss-of-function mutations in BLM, a member of the RecQ helicase family, cause Bloom's syndrome (BS), a rare, recessive genetic disorder that predisposes to many types of cancer. BLM functions in many aspects of DNA homeostasis, including the suppression of homologous recombination (HR) in somatic cells. We investigated whether BLM overexpression, in contrast with loss-offunction mutations, attenuated the intestinal tumor phenotypes of Apc Min/þ and Apc Min/þ ;Msh2 À/À mice, animal models of familial adenomatous polyposis coli (FAP). We constructed a transgenic mouse line expressing human BLM (BLM-Tg) and crossed it onto both backgrounds. BLM-Tg decreased adenoma incidence in a dose-dependent manner in our Apc Min/þ model of FAP, although levels of GIN were unaffected and concomitantly increased animal survival over 50%. It did not reduce intestinal tumorigenesis in Apc Min/þ ;Msh2 À/À mice. We used the pink-eyed unstable (p un ) mouse model to demonstrate that increasing BLM dosage in vivo lowered endogenous levels of HR by 2-fold. Our data suggest that attenuation of the Min phenotype is achieved through a direct effect of BLM-Tg on the HR repair pathway. These findings demonstrate that HR can be manipulated in vivo to modulate tumor formation at the organismal level. Our data suggest that lowering HR frequencies may have positive therapeutic outcomes in the context of specific hereditary cancer predisposition syndromes, exemplified by FAP. Cancer Prev Res; 8(7); 650-6. Ó2015 AACR.
Introduction
The RecQ-like helicase family members WRN, BLM, and RECQL4 are linked to human genetic diseases characterized by genome instability, premature aging, and cancer predisposition (1, 2) . BLM is a structure-specific helicase with 3 0 -5 0 directionality which is involved in DNA double-strand break (DSB) repair (3) . BLM functions in many aspects of DNA homeostasis, including the restart/repair of stalled and collapsed replication forks during DNA replication, repair of interstrand cross-links, and resolution of Holliday junctions (4) (5) (6) . While it is accepted that BLM promotes resolution of Holliday intermediates by dissolution, thus suppressing crossovers, the role of BLM in homologous recombination (HR) is more complex than merely this late stage role. BLM also disrupts formation of RAD51-ssDNA filaments, leading to disruption of D-loops and thus suppression of HR at earlier stages (7) . BLM-deficient cells have an approximate 10-fold increase in the number of sister chromatid exchanges (SCE) caused by inappropriate HR between sister chromatids at the S or G 2 phases of the cell cycle (8) . Bloom's syndrome (BS) is a rare, recessive genetic disorder that is caused by loss-of-function mutations in the BLM gene (9) . BS patients have a predisposition to develop many types of cancer, presenting with a mean age of 24 years at diagnosis.
Several lines of evidence indicate that Blm dosage is critical for controlling the onset of tumorigenesis in mice. Mouse models demonstrate that chromosomal instability directly correlates with the levels of Blm; as Blm decreases, genomic instability and tumor burden increase (10) (11) (12) . In addition, haploinsufficiency for Blm on the C57Bl-6J Apc Min/þ background increases spontaneous adenoma formation and dysplasia (11) . Genomic analyses of Apc Min/þ ;Blm Cin/þ mice indicate that increased adenoma formation is a direct consequence of reduced Blm levels and an increase in somatic recombination. This, in turn, facilitates loss of the wildtype Apc allele by interchromosomal recombination and leads to increased loss-of-heterozygosity (LOH). In humans, similar conclusions have been reached about carriers of specific BLM mutations and their resulting susceptibilities to colorectal cancer (13) .
Familial adenomatous polyposis coli (FAP) is a hereditary human cancer predisposition syndrome characterized by the growth of hundreds to thousands of small adenomatous polyps throughout the colon (reviewed in ref. 14) . FAP requires the inheritance of a mutated allele of the adenomatous polyposis coli (APC) gene (15) . Depending on the nature of the inherited germline allele, second-hit inactivation of the wild-type allele is achieved either by LOH of the APC locus or intragenic mutation of the APC gene (16) . APC is also inactivated by intragenic mutation in 70% to 80% of individuals with sporadic colorectal cancer (14) .
Given the demonstrated relationship between low or absent expression levels of BLM and cancer, we investigated whether constitutive overexpression of BLM modulated adenoma formation in the Apc
Min/þ mouse model of FAP (17) . We hypothesized that if halving Blm gene dosage increased predisposition to tumorigenesis, overexpression would conversely decrease tumor susceptibility. Understanding the mechanism by which BLM attenuates tumor susceptibility will aid our fundamental understanding of its roles in maintaining genomic stability and suggest new strategies for cancer prevention involving direct regulation of DNA repair pathways. Our data suggest that levels of specific DNA repair proteins may be titrated to achieve positive therapeutic outcomes in the context of specific hereditary cancer syndromes, exemplified by FAP.
Materials and Methods

Generation of the transgenic mouse line expressing BLM
The procedure is outlined below. The human BLM cDNA was amplified from plasmid pJK1 and cloned into the TA-vector (Promega). The construct was sequenced and verified. A 0.44 kb fragment, corresponding to the phosphoglycerate kinase (PGK) promoter, was cloned in to the 5 0 end of the BLM cDNA. The PGK-BLM cDNA fragment was then cloned into the vector pOPRSVICat, containing a synthetic intron and the HSV thymidine kinase (TK) polyadenylation signal. The PGK-BLMcDNA-p(A) fragment was removed by restriction digestion from the vector, purified, and introduced into C57Bl-6J oocytes by pronuclear injection. Founder lines were generated and initially screened for the presence of the transgene by Southern blotting. A probe corresponding to the 3 0 end of the BLM cDNA was used. Once germline transmission had been established, transgenic animals were routinely identified using PCR.
Generation of mice lines and genotyping
Apc Min/þ mice were originally obtained from The Jackson Laboratories (stock: 002020; strain: C57BL/6J-Apc Min /J). Blm Cin/þ mice have been previously reported (11) . The pinkeyed unstable mouse model (18) 
, and BLM-Tg lines were intercrossed to generate mice of the required genotypes, all on congenic C57BL/6J backgrounds. Animals were bred in a barrier facility and were maintained according to the NIH animal care and use guidelines. Both male and female mice were included in experimental study groups for subsequent analyses. All experiments involving animals received prior approval from the OSU Institutional Animal Care and Use Committee. Apc Min/þ , Blm Cin/þ and Msh2 þ/À mice were genotyped as described previously (11, 19) .
Genotyping BLM-Tg mice Mice were genotyped as follows: primers hBE3F (5 0 -TAT GCA CTA CCC AAA ACA CAC C-3 0 ; forward) and hBE3R (5 0 -TCA GTC AAA TCT ATT TGC TCG C-3 0 ; reverse) were used in a PCR reaction to amplify a 310 bp product from exon 3 of human BLM. Primers HMGAPF (5 0 -GAC ATC AAG AAG GTG GTG AAG-3 0 ; forward) and HMGAPR (5 0 -CCA GGA AAT GAG CTT GAC AAA G-3 0 ; reverse) were used to amplify a 171 bp product from mouse Gapdh as an internal positive control. PCR reactions were performed with standard Taq polymerase.
qPCR to determine allelic status of BLM-Tg Primers BLM09F (5 0 -TGG TGC GGA AGT GAT TTC AGT A-3 0 ; forward) and BLM12R (5 0 -TTT ATA GGC TTC GGT GGA GC-3 0 ) were used to amplify a 396 bp amplicon from the 3 0 end of the BLM cDNA. The SYBR Green PCR Master Mix (Invitrogen) was used for all qPCR reactions. Purified DNAs from BLM-Tg mice were used as templates. Reactions were performed with a series of dilutions of each template. Cycle threshold (C t ) was plotted against log 10 [DNA] and used to identify hemizygous (BLM þ/T ) and homozygous (BLM T/T ) transgenic mice. All qPCR reactions were run in triplicate and repeated at least twice.
Animal dissection
Mice were euthanized at 16 weeks by CO 2 inhalation, followed by cervical dislocation. Intestines were removed, rinsed in PBS, and cut into sections corresponding to the duodenum, jejunum, ileum, cecum, and colon (large intestine). Tissues were opened longitudinally, washed twice in PBS, and examined under a dissecting microscope. Gross numbers of adenomas/intestinal polyps were counted. Tissues were fixed in 10% formalin overnight, blocked in paraffin, sectioned, and stained with hematoxylin and eosin. Slides were evaluated to confirm tumors and determine gastrointestinal neoplasia (GIN). The criteria for GIN are as described previously (20) .
Ethics statement
All experiments involving mice received prior approval from The Ohio State University Institutional Animal Care and Use Committee (IACUC), OLAW Assurance #A3261-01. Animal work was conducted in accordance with the established criteria of our animal use protocol, #2012A00000021, approved by IACUC. Mice were observed on a daily basis for predetermined criteria necessitating removal and euthanasia. Decisions to remove animals were made in conjunction with the veterinarian staff of our animal facility. Mice were euthanized by CO 2 inhalation, followed by cervical dislocation.
Dissection of the RPE/scoring reversion events
These have been described previously (18) .
Statistical analysis
All statistical analyses were performed with Prism 6.1.
Results
BLM expression rescues the embryonic lethality of the Blm
Cin knockout mouse A transgenic mouse was generated that expressed human BLM on a congenic C57Bl-6J background, hereafter designated BLM-Tg. qPCR was used to establish the allelic status of the BLM transgene in sibling mice bred from the established colony ( Supplementary  Fig. S1 ). Protein expression levels correlated with the allelic status of the transgene; homozygous (BLM T/T ) mice expressed approximately twice as much BLM as hemizygous (BLM þ/T ) mice. The
Long-term expression of BLM for over 24 months had no apparent deleterious effects on animal health. BLM-Tg mice (n ¼ 3) were subjected to full necropsy and phenotypic analyses. No overt phenotypic abnormalities were detected; only age-or strainrelated lesions were observed (data not shown). Tumors were not apparent in any tissue at necropsy, and there was no evidence of architectural destruction or invasion which would suggest neoplastic transformation.
Transgenic expression of BLM reduces adenoma numbers in Apc Min/þ mice The BLM-Tg line was crossed to Apc Min/þ mice, also on a C57Bl-6J background. Animals were maintained in a barrier environment, and four different groups of litter mates were generated:
;BLM T/T , and (iv) BLM þ/T and/or wild-type mice. Mice were euthanized after 16
weeks and gross intestinal adenomas were counted with a dissecting microscope to differentiate adenomas in the duodenum, jejunum, ileum, cecum, and colon. Pathology studies confirmed and categorized adenomas as low-or high-grade and scored GIN according to the criteria of Boivin and colleagues as an early marker for neoplasia (20) .
BLM-Tg significantly reduced gross numbers of intestinal adenomas in Apc
Min/þ litter mates ( Fig. 1A ; 1B) , which is not surprising, as these regions comprise the predominant site of adenoma formation in the Apc Min/þ mode (17) . There was no difference in mean adenoma numbers between male and female mice. Adenomas were not observed in control groups of BLM-Tg or wild-type mice.
Despite the reduction in total adenomas by BLM-Tg, there was no significant reduction in the levels of GIN between groups (Fig. 1A) ;BLM T/T mice. However, these sample sizes confer only a 30% power to detect differences between means of 1.56 with a significance level (a) of 0.05 (two-tailed).
We would require 80 or more animals in each group to have 80% power to detect a difference between means of 1.34 with a significance level (a) of 0.05 (two-tailed).
BLM-Tg increases survival in the Apc
Min/þ mouse model of intestinal tumorigenesis
Survival of Apc Min/þ mice was increased by the BLM transgene (Fig. 2) ;BLT T/T mice was consistent with the well-characterized etiology of tumor development in the Apc Min/þ model ( Fig. 3A-F 
;Blm
Cin/þ mice, and 4 mice also developed adenocarcinomas that invaded the serosa (Fig. 3H ). There was a statistically significant increase in both carcinomas and high-grade dysplasia in the Apc Min/þ ; Blm Cin/þ mice (P < 0.0001). These data suggest that Blm/BLM dosage can modulate tumor burden and progression in the mouse. Although BLM-Tg most likely suppresses adenoma formation by inhibiting progression from GIN to intestinal adenoma, it may also have subtle effects on the initiation of dysplasia that this study is not sufficiently powered to reveal.
Transgenic BLM does not attenuate intestinal tumor numbers in mismatch repair-deficient Apc Min/þ mice A well-documented aspect of the Apc Min/þ phenotype on the C57Bl-6J background is that inactivation of the wild-type Apc locus by LOH is essential for subsequent intestinal adenoma formation (17) . Given the known roles of Blm/BLM in HR, we investigated if our transgenic BLM could likewise reduce numbers of intestinal adenomas in an Apc Min/þ model that was not dependent on LOH as a second-hit mechanism of inactivation. It has been observed that when Apc Min/þ is combined with mismatch repair (MMR)-null mouse models, either Mlh1 À/À or Msh2 À/À , the mechanism of Apc inactivation changes from that of LOH to intragenic mutation. Analyses of adenomas from Mlh1
Min/þ and Msh2 À/À ;Apc Min/þ mice demonstrated intragenic (point) mutation of the wild-type Apc allele in 81% and 85% of cases, respectively (23, 24) . This shift is most likely due to the characteristic mutator phenotypes inherent to these specific models of MMR deficiency. Analyses of respective control groups of Apc Min/þ mice from both of the above models confirmed LOH in all of the adenomas examined (23, 24 
4). This striking increase in intestinal adenomas is a characteristic feature of MMR-deficient Apc
Min/þ mice phenotypes (23) (24) (25) (26) . Our data suggest that when Apc is inactivated by intragenic mutation in this model, rather than by LOH, transgenic BLM has no significant effect on the outcome of intestinal adenoma development.
Overexpression of BLM modulates DNA repair by downregulating HR Given the known role of BLM in maintaining genomic integrity (1, 2), we hypothesized that BLM-Tg ameliorated tumorigenesis in Apc Min/þ mice by suppressing HR. To investigate this possible mechanism, BLM-Tg mice were crossed to the pink-eyed unstable (p un ) mouse model which measures in vivo HR levels. In this model, a somatic intrachromosomal deletion within the mouse p gene restores melanin production in the otherwise transparent cells of the retinal pigment epithelium (RPE), generating a clone of brown cells, or eye-spot (18) . This deletion event occurs spontaneously and is dependent on HR. Thus, the number of RPE eye-spots represents an in vivo read-out for HR. Cohorts of p un/un and p un/un ;BLM T mice were euthanized after 20 days, and RPE eye-spots were counted. Representative examples are shown in Fig. 5A and B. In contrast with Apc Min/þ mice, BLM-Tg dosage does not appear to be a critical modifier in the p un/un model; differences in eye-spot numbers for p un/un ;BLM þ/T and p un/un ; BLM T/T mice were not significant. Mitotic cell division is essentially complete in the RPE by P20 (27) , so it is possible that the restricted developmental window of this tissue is insufficient to highlight subtle differences in HR between p un/un ;BLM þ/T and p un/un ;BLM T/T genotypes. Therefore, these mice were combined and analyzed as one group (Fig. 5C ). The number of eye-spots in control p un/un mice of 6.9 AE 3.2 is comparable with previous reports (18, 28) , whereas BLM overexpression reduces HR 2-fold, resulting in 3.4 AE 1.9 eye-spots per RPE in p un/un ;BLM T mice (P < 0.0001; Mann-Whitney U test). Although it was not possible to directly measure HR in the intestinal epithelial compartment of Abbreviations: ce., cecum; co., colon; du., duodenum; il., ileum; je., jejunum.
Figure 2.
Transgenic BLM increases survival in Apc Min/þ mice. Groups of BLM þ/T and/or
and Apc
Min/þ ; BLM T/T (n ¼ 19) mice were aged. Mice were observed on a daily basis for predetermined criteria necessitating removal and euthanasia. Kaplan-Meier plots were generated, and median survival times of each group were calculated. The log-rank test was used to determine the significance of differences in survival.
our intestinal model, our data suggest that the observed reduction in adenoma numbers is also due to modulation of HR by BLM-Tg.
Discussion
Rescue of the Blm Cin/Cin embryonic lethal phenotype by BLM-Tg indicates that expression of this human ortholog is sufficiently regulated, within the physiologic context of our model, to direct normal development in Blm-null mice. Our findings that BLM-Tg reduces adenoma numbers in the Apc Min/þ mouse model of intestinal tumorigenesis (Fig. 1) are consistent with the known role of BLM in HR and its requirement for maintaining genomic integrity (2, 11). Moreover, BLM-Tg expression suppressed adenoma formation in the Apc Min/þ model by a dose-dependent mechanism (Fig. 1) , suggesting that augmentation of the HR pathway may be a viable objective for attenuating tumor suppression in specific in vivo milieus, notably the intestinal compartment. Reduction of intestinal tumor burden results in accompanying dose-dependent increases in median survival times for Apc Min/þ ;BLM þ/T and Apc Min/þ ;BLM T/T mice (Fig. 2) . Adenomas that developed in Apc Min/þ ;BLM þ/T mice were pathologically identical to those from Apc Min/þ animals ( Fig. 3) , indicating that the BLM-Tg did not affect tumor origin or skew tumor spectrum in this intestinal model. Furthermore, long-term expression does not adversely alter the wild-type phenotype of BLM þ/T and BLM T/T mice. Mice (n ¼ 12) have now been aged for over 24 months without deleterious effects on survival or overt signs of tumorigenesis. This is somewhat surprising because data from the p un model indicate that, mechanistically, BLM-Tg overexpression downregulates HR 2-fold (Fig. 5) . However, given the crucial function of HR in mediating error-free repair of DNA damage, it is possible that aging BLM-Tg mice may ultimately prove more susceptible to spontaneous tumorigenesis. Perhaps if aged mice were challenged with radiomimetic agents, the inflicted DNA damage might exceed their (lowered) threshold for HR repair, consequently resulting in an increased susceptibility to tumorigenesis. Transgenic mouse lines have also been generated for Wrn, another member of the RecQ helicase family (29) . Although the wild-type Wrn transgene has yet to be tested in models of tumorigenesis, it has no effect on HR in RPE cells of the p un mouse (30) . The elevated BLM levels observed in our Apc
Min/þ
;BLM-Tg model most likely reduce adenoma formation through suppression of HR, thus maintaining heterozygosity of the wild-type Apc allele. We used the p un and MMR-deficient Msh2 À/À models to further investigate the mechanism of tumor reduction in the Apc Min/þ ;BLM T mice, rather than attempting to correlate a reduction in surrogate markers of HR, such as Rad51 foci, with reduction in adenoma burden. These genetic models presented a more relevant system for assessing the effects of the BLM-Tg on HR in vivo. ;Msh2 À/À mice (Fig. 4) . If BLM-Tg was affecting adenoma formation through other mechanisms unrelated to HR, one would predict that adenoma numbers should still differ between these two models. This is not the case. Consistent with this model, levels of GIN are also reduced between Apc Min/þ and Apc Min/þ ;BLM-Tg genotypes, although they do not meet statistical significance (Fig. 1A) . If correct, BLM-Tg would act before the potential onset of GIN, since GIN pathologically precedes adenomas in the Apc Min/þ model and since LOH of the wild-type Apc allele is a fundamental requirement for GIN development on a C57Bl-6J background (31) . In addition to perturbing LOH, and hence subsequent levels of GIN and adenomas, it is possible that BLM-Tg may selectively target neoplastic cells after they have emerged as larger lesions on the Apc Min/þ background. It remains unclear whether elevating BLM levels could eliminate, perhaps through apoptosis, single or small populations of nascent cells that have acquired two mutant alleles of Apc.
Data from our Apc Min/þ
;BLM T models suggest that levels of specific DNA repair proteins may be titrated to achieve positive therapeutic outcomes in the context of specific hereditary cancer syndromes, exemplified by FAP. There are many inhibitors readily available that target the HR repair pathway and downregulate HR (reviewed in refs. 32, 33) . However, we are unaware of any smallmolecule inhibitors, or other reagents, that effect upregulation of endogenous BLM and thus, might prove more suitable for therapeutic applications. With this in mind, we are investigating expression profiles of our BLM-Tg model to determine if there are other molecular targets that are more amenable to therapeutic modulation.
Our study establishes that BLM expression can be effectively manipulated in a mouse model of intestinal tumorigenesis to successfully attenuate the tumor phenotype. We show that overexpression of human BLM reduces intestinal adenoma formation in the Apc Min/þ mouse model and propose that the mechanism is through downregulation of the HR repair pathway. This presents the potential to explore new avenues for intestinal tumor prevention by controlling levels of BLM expression or other genes of the DNA repair pathways. Our data demonstrate the therapeutic potential of titrating levels of specific DNA repair proteins that may be protective against tumor formation and suggest that this approach of modulating fundamental DNA repair pathways may be a viable pharmacologic strategy for cancer prevention.
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